AETHLON MEDICAL financials
$6.380.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.6M | -$1.9M | -$2.1M | -$1.5M | -$1.8M | -$2.0M | -$1.8M | -$2.9M | -$2.6M | -$2.5M | -$3.6M | -$3.2M |
| Net income | -$1.5M | -$1.9M | -$2.0M | -$1.5M | -$1.8M | -$6.3M | -$1.8M | -$2.8M | -$2.6M | -$2.4M | -$3.5M | -$3.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-4.02 | $-6.57 | $-12.25 | $-18.70 | $-42.42 | $-63.02 | $-50.25 | $-80.55 | $-138.00 | $-370.37 | $-548.00 | $-488.00 |
| EBITDA | -$1.5M | -$1.8M | -$2.0M | -$1.4M | -$1.7M | -$1.9M | -$1.7M | -$2.8M | -$2.5M | -$2.4M | -$3.5M | -$3.1M |
| Operating cash flow | -$1.9M | -$1.8M | -$1.9M | -$1.7M | -$1.7M | -$1.7M | -$2.0M | -$2.2M | -$1.7M | -$2.6M | -$2.4M | -$2.7M |
| Free cash flow | -$1.9M | -$1.8M | -$1.9M | -$1.7M | -$1.7M | -$1.7M | -$2.0M | -$2.2M | -$1.7M | -$2.6M | -$2.4M | -$2.7M |
| Diluted shares | 0.4M | 0.3M | 0.2M | 0.1M | 0.0M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.9M | $5.0M | $7.0M | $5.9M | $3.8M | $5.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $6.2M | $6.3M | $8.1M | $7.3M | $5.3M | $7.4M |
| Total liabilities | $1.0M | $1.4M | $1.3M | $1.6M | $1.9M | $2.2M |
| Shareholders' equity | $5.2M | $4.9M | $6.7M | $5.7M | $3.4M | $5.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology